menu
    • menu

    Company profile for Amarin

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmarinIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    Spaces South Docklands Block C 77 Sir John Rogerson's Quay Dublin 2, D02 Vk60
    Telephone
    Telephone
    1-855-827-2372
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://amarincorp.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/amarin-corporation
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    New REDUCE-IT Analysis Reinforces Benefit Of Icosapent Ethyl
    New REDUCE-IT Analysis Reinforces Benefit Of Icosapent Ethyl

    09 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/09/3184162/18362/en/New-REDUCE-IT-Aspirin-Analysis-Presented-at-AHA-Scientific-Sessions-2025-Reinforces-VASCEPA-VAZKEPA-Icosapent-Ethyl-Reduced-Cardiovascular-Events-in-High-Risk-Patients.html

    GLOBENEWSWIRE
    09 Nov 2025
    Share Share
    Amarin To Showcase REDUCE-IT Data Strength at AHA 2025
    Amarin To Showcase REDUCE-IT Data Strength at AHA 2025

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179271/18362/en/Amarin-To-Present-New-Analyses-Affirming-Robustness-of-Data-from-REDUCE-IT-and-Additional-Mechanisms-of-Action-of-Eicosapentaenoic-Acid-EPA-at-American-Heart-Association-AHA-Scient.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Amarin Reports Third Quarter 2025 Financial Results
    Amarin Reports Third Quarter 2025 Financial Results

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176292/18362/en/Amarin-Reports-Third-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Amarin Supports FDA Labeling Revision On Fenofibrate, Affirming
    Amarin Supports FDA Labeling Revision On Fenofibrate, Affirming

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174541/18362/en/Amarin-Issues-Statement-Supporting-FDA-s-Action-to-Revise-Labeling-for-Fenofibrate-Drugs-Reinforcing-a-Lack-of-Cardiovascular-Benefit.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Amarin To Present Q3 2025 Financials, Conduct Conference Call
    Amarin To Present Q3 2025 Financials, Conduct Conference Call

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3167038/18362/en/Amarin-to-Report-Third-Quarter-2025-Financial-Results-and-Host-Conference-Call-on-October-29-2025.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    Amarin, HLS Present REDUCE-IT & EPA Mechanistic Data at Congress
    Amarin, HLS Present REDUCE-IT & EPA Mechanistic Data at Congress

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3166085/18362/en/Amarin-and-HLS-Therapeutics-Collaborate-on-Presenting-REDUCE-IT-and-EPA-Mechanistic-Data-at-the-Canadian-Cardiovascular-Congress.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search